Tectonic Therapeutic, Inc.
TECXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tectonic Therapeutic, Inc. focuses on Biotechnology services and products. Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). The company carries a $615.1M market cap, placing it firmly in the small-cap category. It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Market Cap
$615.1M
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
-6.97
EPS (TTM)
$-4.74
EPS (Fwd)
$-4.68
ROE
-31.4%
ROA
-20.7%
Cash
$236.9M
Total Debt
$4.6M
Free CF
-$44.7M
52W Change
48.8%
Annual Financials
Cash vs Debt
Tectonic Therapeutic, Inc. holds $236.9M in cash against $4.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$44.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -31.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Tectonic Therapeutic, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, TECX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tectonic Therapeutic, Inc. and its sector.